UAE Clinical Research Organization (CRO): MOHAP Trial License Guide 2026

Updated August 2026. The UAE has positioned itself as one of the most strategically attractive clinical research environments in the Middle East and North Africa (MENA) region — driven by a multicultural population providing unmatched ethnic diversity for trial recruitment, world-class hospital infrastructure, a MOHAP clinical trials regulatory framework aligned with ICH guidelines, and government initiatives to make the UAE a regional pharmaceutical innovation hub. For clinical research organizations (CROs), site management organizations (SMOs), and international sponsors seeking to establish or expand trial operations in the Gulf, this guide covers MOHAP clinical trial registration, GCP certification, IRB/ethics committee approvals across all three UAE regulators, trial types (Phase I–IV, BA/BE studies), DIFC/ADGM incorporation for international CRO branches, and realistic per-site setup costs of AED 200,000–2,000,000.

UAE Clinical Research Regulatory Framework: MOHAP, DHA, and DOH

Clinical research in the UAE operates under a dual-layer regulatory system: federal oversight by the Ministry of Health and Prevention (MOHAP) through its Clinical Trial Department, and emirate-level ethics oversight through separate Institutional Review Boards (IRBs) or Research Ethics Committees (RECs) established by DHA (Dubai) and DOH/HAAD (Abu Dhabi). Understanding this structure is essential for CROs and sponsors, because different approvals are required depending on the emirate(s) where trial sites are located.

MOHAP’s Clinical Trial Department is the national authority for clinical trial registration, investigational medicinal product (IMP) authorization, and trial inspection. All clinical trials involving medicinal products conducted in UAE healthcare facilities — regardless of emirate — must be registered with MOHAP and receive an IMP authorization (equivalent to a Clinical Trial Authorization or IND). MOHAP’s clinical trial regulation is broadly aligned with the ICH E6(R2) Good Clinical Practice guidelines and draws on the EU Clinical Trials Directive and FDA 21 CFR Parts 312 and 320 frameworks as reference standards, though MOHAP’s specific requirements may differ in procedural details.

The DHA Research Ethics Committee provides ethics approval for trials conducted at DHA-licensed facilities in Dubai. The HAAD/DOH Abu Dhabi Healthcare Research Ethics Committee provides ethics approval for trials at DOH-licensed facilities in Abu Dhabi. Trials being conducted at sites in both emirates require ethics approval from both committees — there is no cross-recognition of ethics approvals between DHA and DOH RECs as of 2026. Additionally, many individual hospitals and research institutions maintain their own Institutional Review Boards that must also approve trials conducted at their facility, creating a multi-level ethics approval stack for multi-site UAE trials.

MOHAP Clinical Trial Registration: Process, Fees, and Timeline

All clinical trials involving investigational medicinal products (IMPs) conducted in the UAE must be registered with MOHAP’s Clinical Trial Department before any patient recruitment can begin. The registration and IMP authorization process involves several stages:

Pre-submission meeting: For novel investigational products or complex trial designs, MOHAP offers pre-submission consultation meetings where sponsors and CROs can discuss the trial protocol with MOHAP clinical trial specialists before formal submission. This is not mandatory but is strongly recommended for Phase I trials or trials involving biologics, cell therapies, or gene therapies.

Clinical trial dossier submission: The MOHAP clinical trial dossier follows an ICH-aligned structure including: Investigator’s Brochure (IB) or Investigational Medicinal Product Dossier (IMPD), clinical protocol (per ICH E8/E9), informed consent form (Arabic and English versions — both mandatory for UAE trial participants), investigator CVs and GCP certificates, ethics committee approval letters from the applicable UAE RECs, site qualification documentation for each clinical site, and IMP analytical and manufacturing documentation. The submission is made through MOHAP’s e-service portal with specified document formats and naming conventions.

MOHAP review timeline and fees: MOHAP targets a 30–60 day review timeline for standard clinical trial submissions, with possible requests for additional information extending this to 90–120 days for complex dossiers. MOHAP clinical trial registration fees range from AED 50,000–150,000 depending on the trial phase — Phase I trials command the highest fees due to their first-in-human nature and the level of MOHAP regulatory oversight required. Phase II–III trials fall in the AED 50,000–100,000 range. BA/BE studies, as the most standardized trial type, are typically at the lower end of the fee range.

Good Clinical Practice (GCP) and ICH E6(R2) Certification Requirements

Good Clinical Practice (GCP) is the international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials. The UAE adopts the ICH E6(R2) guideline as its primary GCP reference standard. All personnel directly involved in UAE clinical trial conduct — Principal Investigators, Sub-Investigators, Clinical Research Coordinators (CRCs), CRO monitors, data managers, and pharmacovigilance staff — must hold a current GCP certification.

GCP certification in the UAE context is typically obtained through: MOHAP-recognized GCP training courses (available from MOHAP itself and from approved international training providers), ICH E6(R2)-aligned online training programs from providers such as CITI Program, TransCelerate, or academic medical centers, or GCP workshops delivered at UAE hospital research departments. Certificates must be current — MOHAP and ethics committees typically require GCP certificates dated within 2–3 years of the trial initiation. Investigators with lapsed certificates will face delayed site initiation visits (SIVs) until recertification is complete.

ICH E6(R2) introduced the concept of Risk-Based Monitoring (RBM) as an evolution from traditional 100% source data verification (SDV) monitoring. UAE clinical trials under MOHAP can use RBM approaches provided the CRO’s monitoring plan is pre-approved as part of the trial dossier. Adopting RBM can significantly reduce monitoring visit costs for large multi-site UAE trials, a consideration for CROs building UAE business cases for sponsors.

IRB/Ethics Committee Approval: MOHAP, DHA, and DOH Processes

Ethics committee approval is a prerequisite for MOHAP clinical trial registration — MOHAP requires evidence of ethics committee approval as part of the IMP authorization dossier. The multi-committee structure of UAE clinical research ethics oversight creates significant administrative overhead for multi-site trials:

MOHAP National Research Ethics Committee: The federal-level ethics body overseen by MOHAP, with jurisdiction over trials at MOHAP-affiliated facilities and federal health institutions. MOHAP’s National Ethics Committee operates with defined submission deadlines (typically monthly review cycles) and a standard turnaround of 6–10 weeks for initial review. Submission requires protocol, IB/IMPD, informed consent forms, investigator information, and evidence of scientific peer review (for novel first-in-class therapies).

DHA Research Ethics Committee (Dubai): Reviews trials at DHA-licensed facilities. Submission requirements broadly align with MOHAP but with DHA-specific forms and submission procedures through the Sheryan portal. Timeline is 4–8 weeks for standard submissions. DHA’s REC meets at defined intervals — submission deadlines must be confirmed with DHA’s Health Research Division to ensure review at the next scheduled meeting.

DOH/HAAD Abu Dhabi Healthcare Research Ethics Committee: Reviews trials at DOH-licensed facilities. Uses the DOH research ethics submission system. Timeline is 6–10 weeks. Abu Dhabi’s research ethics framework has been progressively strengthened since the HAAD era, with DOH now requiring more rigorous scientific review for novel Phase I and Phase II trials.

For CROs operating multi-emirate trial sites, allow 3–6 months for the full ethics and MOHAP approval stack to be completed before site initiation. Parallel submission to all applicable ethics committees (and MOHAP) simultaneously, while procedurally complex, is permitted and is the recommended approach for timeline compression.

Phase I to Phase IV Trial Types in the UAE

The UAE’s clinical research environment accommodates the full range of clinical trial phases, with distinct regulatory, site infrastructure, and economic characteristics at each phase:

Phase I trials (First-in-Human): The most resource-intensive trial type, requiring dedicated Phase I clinical units with 24-hour medical monitoring capability, emergency response capacity, and intensive clinical laboratory support. Phase I units in UAE typically operate within major private hospitals (Mediclinic City Hospital, Cleveland Clinic Abu Dhabi, Saudi German Hospital Dubai) with specialized unit designs. MOHAP scrutiny on Phase I trials is highest — MOHAP may conduct pre-trial site inspections and requires evidence of Phase I trial experience at the site. Setup cost for a dedicated Phase I unit: AED 1,000,000–2,000,000.

Phase II trials (Proof of Concept): Generally feasible at specialist outpatient clinics or hospital-based research departments with adequate patient recruitment catchments. Phase II trials in the UAE benefit from the country’s multicultural population for trials requiring specific ethnic subgroups or patients from countries not well-represented in Western Phase II programs. Setup cost per Phase II site within an existing hospital: AED 200,000–600,000 (covering research coordinator salaries, IRB fees, protocol-specific equipment, and trial management systems).

Phase III trials (Pivotal Efficacy): UAE Phase III sites are attractive to global sponsors because the UAE’s multicultural population allows recruitment of South Asian, Arab, and East Asian patients in a single GCP-compliant environment. For therapeutic areas like diabetes (very high UAE prevalence at 17% adult population), cardiovascular disease, and oncology, UAE Phase III sites offer strong recruitment potential. Setup cost per Phase III site: AED 300,000–800,000.

Phase IV / Post-Marketing Surveillance: Increasingly common in UAE as pharmaceutical companies seek real-world evidence data in Gulf populations that differ metabolically and epidemiologically from Western trial populations. Phase IV studies have lower site infrastructure requirements and lower MOHAP registration fees.

Bioavailability/Bioequivalence (BA/BE) studies: The dominant trial category by volume in UAE. MOHAP requires local BA/BE studies for the registration of generic pharmaceutical products, creating a sustained demand for UAE BA/BE facility capacity. BA/BE studies use healthy volunteer subjects under tightly controlled conditions, requiring dedicated clinical pharmacology units with controlled diet, rest, and 24-hour subject monitoring. UAE’s growing generic pharmaceutical manufacturing sector (Julphar, Al Hayat, Tabuk Pharmaceuticals) generates significant BA/BE trial demand that local CROs can capture.

Site Management Organization (SMO) Model and DIFC/ADGM Incorporation

A Site Management Organization (SMO) is a specialized company that manages the operational aspects of clinical trial conduct at clinical sites, providing trained CRCs, regulatory submission support, patient recruitment coordination, and quality management — enabling hospitals to participate in clinical trials without building full in-house research infrastructure. The SMO model is well-established globally and is increasingly being adopted in UAE as hospital research departments recognize the resource intensity of trial management.

For international CROs establishing UAE operations, the DIFC (Dubai International Financial Centre) and ADGM (Abu Dhabi Global Market) free zones offer compelling corporate structures. Both DIFC and ADGM operate under English common law, allow 100% foreign ownership, provide a recognized legal framework for international contracts and dispute resolution, and grant direct access to DIFC/ADGM’s professional service ecosystem (legal, audit, banking). International CRO branches in DIFC or ADGM can contract with UAE mainland hospitals and academic medical centers for site management services.

The Emirates Clinical Research Association (ECRA) is the primary UAE professional association for clinical research professionals, providing networking, training, and advocacy for the sector. CROs entering the UAE market should engage with ECRA as a relationship-building and credibility-establishing platform.

UAE Clinical Research Market: COVID-19 Trial Legacy and Future Pipeline

The UAE’s participation in landmark COVID-19 vaccine trials — including the Sinopharm Phase III trial that enrolled 125,000+ participants in 2020–2021, and UAE clinical sites’ contributions to the Moderna and Pfizer/BioNTech pivotal studies — established the UAE as a credible large-scale clinical trial jurisdiction with the infrastructure and regulatory agility to support urgent-need trials. This legacy has raised the UAE’s profile with global pharmaceutical sponsors and positioned it as a preferred MENA trial hub for subsequent vaccine and antiviral development programs.

Post-COVID, the UAE clinical research pipeline is concentrated in oncology (driven by Cleveland Clinic Abu Dhabi and Mediclinic Parkview’s cancer programs), metabolic disease (diabetes, obesity — reflecting UAE’s population health profile), cardiovascular medicine, and infectious disease (given MENA’s unique pathogen exposure profile). The UAE Ministry of Economy’s National Strategy for Research, Development, and Innovation allocates funding to clinical research infrastructure as a strategic priority through 2031.

Trial Phase	MOHAP Fee (AED)	Ethics Approvals Needed	Site Setup Cost (AED)
Phase I (First-in-Human)	100,000–150,000	MOHAP + DHA or DOH	1,000,000–2,000,000
Phase II (Proof of Concept)	75,000–100,000	MOHAP + applicable emirate REC	200,000–600,000
Phase III (Pivotal)	50,000–100,000	MOHAP + all emirate RECs where sites located	300,000–800,000
BA/BE Studies	50,000–75,000	MOHAP + applicable emirate REC	200,000–500,000
Phase IV / Post-Marketing	25,000–50,000	MOHAP (notification) + hospital IRB	100,000–300,000

Frequently Asked Questions

What is the MOHAP clinical trial registration fee and how long does approval take?

MOHAP clinical trial registration fees range from AED 50,000–150,000 depending on trial phase, with Phase I trials at the highest fee level (AED 100,000–150,000) and Phase IV post-marketing studies at the lowest (AED 25,000–50,000). BA/BE studies typically fall in the AED 50,000–75,000 range. MOHAP targets a 30–60 day review timeline for standard submissions, but complex dossiers or those triggering additional information requests may take 90–120 days. Parallel submission to UAE ethics committees (DHA, DOH) while MOHAP review is ongoing is permitted and recommended for timeline compression.

Which UAE ethics committee must approve a clinical trial at a Dubai hospital?

Clinical trials at DHA-licensed facilities in Dubai require ethics approval from the DHA Research Ethics Committee. If the same trial also has sites at DOH-licensed facilities in Abu Dhabi, the DOH/HAAD Abu Dhabi Healthcare Research Ethics Committee approval is additionally required — DHA and DOH ethics approvals are not cross-recognized. MOHAP ethics approval is required for trials at MOHAP-affiliated federal facilities. Many hospitals also require approval from their own Institutional Review Board in addition to the regulatory REC approval, creating a multi-level ethics approval process for multi-site UAE trials.

Why are BA/BE studies the most common clinical trial type in UAE?

Bioavailability/bioequivalence (BA/BE) studies are the most common UAE clinical trial type because MOHAP requires local BA/BE data as part of the generic drug registration process — sponsors cannot register a generic pharmaceutical product in the UAE based solely on foreign BA/BE data. The UAE’s growing generic pharmaceutical manufacturing sector (Julphar, Al Hayat, Tabuk) generates sustained demand for BA/BE studies at UAE-based clinical pharmacology units. BA/BE studies also have a well-defined protocol structure (healthy volunteers, controlled conditions, established bioanalytical methods), making them operationally efficient for CROs to execute at scale compared to complex Phase II/III trials.

Can an international CRO operate in UAE through a DIFC or ADGM company?

Yes. Both DIFC (Dubai International Financial Centre) and ADGM (Abu Dhabi Global Market) are recognized corporate jurisdictions for international CRO branch offices or subsidiaries. They operate under English common law, allow 100% foreign ownership, and have well-established banking and professional services infrastructure. A DIFC or ADGM CRO entity can contract with UAE mainland hospitals and research institutions for site management and monitoring services. The CRO entity still needs to register with MOHAP as a clinical research organization and comply with MOHAP’s CRO qualification requirements for specific trial activities. Many global CROs (Covance, PRA Health Sciences, ICON, Syneos) have established their UAE/GCC regional operations through DIFC or ADGM.

What is the ICH E6(R2) GCP requirement for UAE clinical trial investigators?

ICH E6(R2) is the UAE’s reference Good Clinical Practice standard for all clinical trials involving investigational medicinal products. All Principal Investigators, Sub-Investigators, Clinical Research Coordinators, and CRO monitoring staff directly involved in UAE trial conduct must hold current GCP certification — certificates are typically recognized as current for 2–3 years from issuance. GCP training must be from MOHAP-recognized providers or from internationally accredited programs (CITI Program, TransCelerate, academic medical center training). ICH E6(R2)’s Risk-Based Monitoring provisions are recognized by MOHAP and can be incorporated into approved UAE trial monitoring plans, allowing CROs to apply adaptive monitoring approaches that reduce cost while maintaining data quality.